Kestra Medical Technologies (NASDAQ:KMTS) Trading 8.2% Higher – Should You Buy?

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) shares traded up 8.2% on Monday . The company traded as high as $28.70 and last traded at $28.57. 116,495 shares changed hands during trading, a decline of 66% from the average daily volume of 342,883 shares. The stock had previously closed at $26.40.

Analysts Set New Price Targets

A number of analysts have commented on KMTS shares. Weiss Ratings downgraded shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 16th. Wolfe Research set a $30.00 target price on Kestra Medical Technologies in a report on Wednesday, July 15th. BTIG Research upped their price target on Kestra Medical Technologies from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Wall Street Zen raised Kestra Medical Technologies from a “sell” rating to a “hold” rating in a report on Saturday. Finally, JPMorgan Chase & Co. assumed coverage on Kestra Medical Technologies in a research note on Monday. They set an “overweight” rating and a $30.00 price objective on the stock. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Kestra Medical Technologies currently has an average rating of “Hold” and a consensus target price of $28.14.

Kestra Medical Technologies Trading Down 1.6%

The stock has a market capitalization of $1.63 billion, a price-to-earnings ratio of -11.53 and a beta of 0.58. The company’s 50-day moving average is $23.31 and its 200-day moving average is $22.63. The company has a quick ratio of 4.41, a current ratio of 4.41 and a debt-to-equity ratio of 0.16.

Kestra Medical Technologies (NASDAQ:KMTS) last posted its earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.08). Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. The firm had revenue of $28.64 million during the quarter. Research analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.29 earnings per share for the current fiscal year.

Insider Activity

In other Kestra Medical Technologies news, insider Alfred J. Ford, Jr. sold 6,275 shares of the firm’s stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $24.09, for a total transaction of $151,164.75. Following the completion of the sale, the insider owned 99,564 shares of the company’s stock, valued at $2,398,496.76. This trade represents a 5.93% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Timothy P. Moran sold 2,380 shares of Kestra Medical Technologies stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $23.76, for a total value of $56,548.80. Following the completion of the sale, the insider owned 66,345 shares in the company, valued at $1,576,357.20. This represents a 3.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 238,164 shares of company stock worth $5,603,152. 5.30% of the stock is owned by company insiders.

Institutional Trading of Kestra Medical Technologies

A number of hedge funds and other institutional investors have recently modified their holdings of KMTS. California State Teachers Retirement System raised its holdings in Kestra Medical Technologies by 39.2% in the 1st quarter. California State Teachers Retirement System now owns 27,835 shares of the company’s stock valued at $555,000 after buying an additional 7,844 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in shares of Kestra Medical Technologies by 6.6% in the 1st quarter. The Manufacturers Life Insurance Company now owns 92,515 shares of the company’s stock worth $1,844,000 after acquiring an additional 5,731 shares during the last quarter. Quantinno Capital Management LP purchased a new position in shares of Kestra Medical Technologies during the first quarter worth $431,000. Sei Investments Co. boosted its position in shares of Kestra Medical Technologies by 22.6% during the first quarter. Sei Investments Co. now owns 237,116 shares of the company’s stock worth $4,726,000 after buying an additional 43,753 shares during the period. Finally, Spartan Wealth Advisory Services LLC acquired a new stake in shares of Kestra Medical Technologies in the first quarter valued at $603,000.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.